Home › Trials › NCT06467383

Understanding the diagnosis and treatment of early and locally advanced non-small cell lung cancer

A Study to Describe the Diagnostic and Therapeutic Path of Patients with NSCLC in Early Stage and Locally Advanced

Observational MSD Italia S.r.l. · NCT06467383

This study looks at how patients with early and locally advanced non-small cell lung cancer are diagnosed and treated after surgery or radiation to see how well different approaches work.

Quick facts

Study typeObservational
Enrollment600 (estimated)
Ages18 Years and up
SexAll
SponsorMSD Italia S.r.l. Industry-sponsored
Drugs / interventionschemotherapy
Locations25 sites (San Giovanni Rotondo, FG and 24 other locations)
Trial IDNCT06467383 on ClinicalTrials.gov

What this trial studies

This observational study aims to gather real-world evidence regarding the diagnostic and therapeutic pathways for patients with non-small cell lung cancer (NSCLC) in early and locally advanced stages. It focuses on patients who have undergone curative surgery or radiotherapy between January 2018 and June 2019, analyzing their treatment outcomes and follow-up data until January 2021. The study addresses the variability in treatment approaches across different regions and medical centers, highlighting the need for a standardized strategy in managing NSCLC.

Who should consider this trial

Good fit: Ideal candidates include adult patients aged 18 and older with stage I-III NSCLC who have received curative treatment.

Not a fit: Patients without available medical records or those enrolled in studies with specific management strategies may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could lead to improved treatment protocols and better patient outcomes for those diagnosed with NSCLC.

How similar studies have performed: Other observational studies have shown success in improving treatment understanding for similar conditions, indicating that this approach is promising.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

1. Patients with stage I-III NSCLC who have received curative surgery or radiotherapy between January 2018 and June 2019 with available follow-up through January 2021
2. Adult patients (aged ≥ 18 years) at the moment of diagnosis
3. Patients (or their legally acceptable representatives) must have signed and dated the Informed Consent form; privacy Form (ICF). In case of deceased or untraceable patient the investigator before collecting data shall demonstrate and report all necessary measures adopted to contact the patient.

Exclusion Criteria:

1. Patients without availability of medical charts or information required
2. Enrollment in studies imposing a specific patient's management strategy which does not correspond to the site's normal clinical practice.

Where this trial is running

San Giovanni Rotondo, FG and 24 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Non-small Cell Lung CancerNSCLCNSCLC, Stage IIINSCLC, Stage INSCLC early stageNSCLC locally advancedretrospective observational studyReal-World Evidence
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.